Prestige Biologics Co. Ltd. (334970) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Prestige Biologics Co. Ltd. stock KRW 988, price KRW 1,098, that is 10.0% below the price, quality 32 out of 100. Rating: overvalued. Calculated from audited financials with 5 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Prestige Biologics Co. Ltd.
334970 · KQExpensive (fair value 10% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
60‑month range 1,091 KRW – 17,300 KRW · fair‑value band 556.74 KRW – 1,663 KRW · the 1,098 KRW price screens above the 988.35 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether Prestige Biologics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars.
Show moreShow less
Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors.
Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019. The company was founded in 2015 and is based in Cheongju-si, South Korea.
Stock analysis
Prestige Biologics Co. Ltd. (334970) currently trades at 1,098 KRW, while our model-based Fair Value estimate is 988.35 KRW, 10% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 930.71 KRW per share, and 0 of the 5 models we run sit above the 1,098 KRW price.
Bear case: the DCF Models group reads lowest at 492.79 KRW, and 5 of the 5 models stay below the price. Data coverage for this calculation is low.
Scenario range: 556.74 KRW (bear) to 1,663 KRW (bull), the price of 1,098 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Prestige Biologics Co. Ltd. reported revenue of 26.7B KRW in FY2025 versus 3.2B KRW in FY2021, a compound +69.5%/yr. Reported net income was −51.2B KRW in FY2025.
Key figures
Market cap 85.4B KRW (≈ $64.1M) Micro · P/S ratio 32.0 · Return on equity −3,132% · Return on assets (EBIT) −14.0% (5-year average) · Operating margin −1,247% · Revenue growth (YoY) −94.5% · Free cash flow 63.9M KRW · Net debt 94.4B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 71% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −10%, 334970 screens cheaper than that median.
Fair Value models
All 5 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
334970 screens overvalued: fair value 10% below the price. Compare with ST Pharm Co →
Compare Prestige Biologics Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- PEG screener for stocks with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Huons Global Co 084110 | 19,300 KRW | 47,019 KRW | +144% | vs 334970 |
| DongKook Pharmaceutical Co 086450 | 24,400 KRW | 28,372 KRW | +16% | vs 334970 |
| ST Pharm Co 237690 | 70,200 KRW | 61,182 KRW | −13% | vs 334970 |
| Vivozon Pharmaceutical Co 082800 | 2,780 KRW | 2,179 KRW | −22% | vs 334970 |
| Oscotec Inc 039200 | 32,300 KRW | 21,262 KRW | −34% | vs 334970 |
| NatureCell Co 007390 | 21,450 KRW | 11,176 KRW | −48% | vs 334970 |
| Mezzion Pharma Co 140410 | 64,800 KRW | 31,450 KRW | −51% | vs 334970 |
| BINEX Co 053030 | 6,850 KRW | 1,844 KRW | −73% | vs 334970 |
| Caregen Co 214370 | 26,600 KRW | 5,414 KRW | −80% | vs 334970 |
| SHUKRAPHAR SHUKRAPHAR | ₹82.23 | ₹9.14 | −89% | vs 334970 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Prestige Biologics Co. Ltd. (334970) overvalued or undervalued?
What is the fair value of 334970?
What is the quality score of 334970?
What is the price target for Prestige Biologics Co. Ltd. (334970)?
What is the Prestige Biologics Co. Ltd. stock forecast for 2026?
What is the intrinsic value of Prestige Biologics Co. Ltd. (334970)?
Is Prestige Biologics Co. Ltd. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 334970?
How much is Prestige Biologics Co. Ltd. worth?
What do the bullish and bearish scenarios say about 334970?
How solid is the balance sheet of Prestige Biologics Co. Ltd. (334970)?
How far is 334970 from its 52-week high?
Which stocks are comparable to Prestige Biologics Co. Ltd.?
Is Prestige Biologics Co. Ltd. stock attractive at the current price?
How is the fair value of 334970 calculated?
Is it still worth investing in stocks now?
What is the share price of Prestige Biologics Co. Ltd. (334970)?
What should I pay attention to with Prestige Biologics Co. Ltd. right now?
Key figures of Prestige Biologics Co. Ltd.
How large is the market capitalisation of Prestige Biologics Co. Ltd. (334970)?
What is the P/S ratio of Prestige Biologics Co. Ltd. (334970)?
What is the return on equity of Prestige Biologics Co. Ltd. (334970)?
What is the EBIT return on assets of Prestige Biologics Co. Ltd. (334970)?
What is the operating margin of Prestige Biologics Co. Ltd. (334970)?
How fast is revenue growing at Prestige Biologics Co. Ltd. (334970)?
How much free cash flow does Prestige Biologics Co. Ltd. (334970) generate?
How much net debt does Prestige Biologics Co. Ltd. (334970) carry?
Watch Prestige Biologics Co. Ltd. in the live analysis
One click puts Prestige Biologics Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.